Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
After finishing at $6.59 in the prior trading day, Zevra Therapeutics Inc (NASDAQ: ZVRA) closed at $6.85, up 3.95%. In other words, the price has increased by $3.95 from its previous closing price. On the day, 0.68 million shares were traded. ZVRA stock price reached its highest trading level at $7.015 during the session, while it also had its lowest trading level at $6.19.
Ratios:
Our goal is to gain a better understanding of ZVRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.47 and its Current Ratio is at 2.53. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.51.
On October 07, 2024, Guggenheim started tracking the stock assigning a Buy rating and target price of $20.
Maxim Group reiterated its Buy rating for the stock on September 24, 2024, while the target price for the stock was revised from $18 to $25.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 28 ’25 when Watton Corey Michael bought 300 shares for $7.84 per share. The transaction valued at 2,352 led to the insider holds 1,800 shares of the business.
Bode John B bought 10,000 shares of ZVRA for $79,624 on Mar 19 ’25. The Director now owns 40,000 shares after completing the transaction at $7.96 per share. On Feb 13 ’25, another insider, Sangiovanni Timothy J., who serves as the SVP, Finance & Corp Controller of the company, sold 3,000 shares for $7.86 each. As a result, the insider received 23,588 and left with 16,341 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZVRA now has a Market Capitalization of 370693920 and an Enterprise Value of 371775712. For the stock, the TTM Price-to-Sale (P/S) ratio is 15.70 while its Price-to-Book (P/B) ratio in mrq is 9.27. Its current Enterprise Value per Revenue stands at 15.745 whereas that against EBITDA is -4.612.
Stock Price History:
The Beta on a monthly basis for ZVRA is 1.80, which has changed by 0.3866397 over the last 52 weeks, in comparison to a change of 0.049593568 over the same period for the S&P500. Over the past 52 weeks, ZVRA has reached a high of $9.76, while it has fallen to a 52-week low of $4.20. The 50-Day Moving Average of the stock is -11.71%, while the 200-Day Moving Average is calculated to be -10.37%.
Shares Statistics:
The stock has traded on average 444.59K shares per day over the past 3-months and 519110 shares per day over the last 10 days, according to various share statistics. A total of 53.67M shares are outstanding, with a floating share count of 53.53M. Insiders hold about 1.08% of the company’s shares, while institutions hold 62.91% stake in the company. Shares short for ZVRA as of 1741910400 were 5573115 with a Short Ratio of 12.54, compared to 1739491200 on 5776931. Therefore, it implies a Short% of Shares Outstanding of 5573115 and a Short% of Float of 10.33.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
